Company Filing History:

10 out of 4,455

Pfizer Corporation

patents

1 out of 2,538

Warner-lambert Company

patents

1 out of 2

Pfizer Pharmaceuticals, Inc.

patents

Years Active: 1992-2003

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6653313 - 1,4-dihydropyridine compounds as bradykinin antagonists (2003-11-25),

2. 6444677 - 5-membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists (2002-09-03),

3. 6291520 - Hydroxamic acid and N-hydroxyurea derivatives and their use (2001-09-18),

4. 6156752 - Optically active 1,4-dihydropyridine compounds as bradykinin antagonists (2000-12-05),

5. 6131226 - 1,4-dihydropyridine compounds as bradykinin antagonists (2000-10-17),

6. 5861402 - 1,4-dihydropyridine compounds (1999-01-19),

7. 5541218 - Indolinyl N-hydroxyurea and N-hydroxamic acid derivatives as (1996-07-30),

8. 5521212 - Cyclopropyl N-hydroxyurea and N-hydroxyacetamides which inhibit (1996-05-28),

9. 5478822 - Tetrahydrobenzazepine derivatives which inhibit lipoxygenase (1995-12-26),

10. 5384320 - N-hydroxyurea derivatives which inhibit lipoxygenase (1995-01-24),

11. 5256789 - Antiinflammatory hydroxamic acids and N-hydroxyureas (1993-10-26),

12. 5104874 - Benzoquinone antiallergy and antinflammatory agents (1992-04-14),

Title: The Innovative Contributions of Takafumi Ikeda

Introduction

Takafumi Ikeda is a notable inventor based in Handa, Japan, recognized for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 12 patents to his name, Ikeda's work primarily focuses on developing compounds that serve as bradykinin antagonists, critical for various therapeutic applications.

Latest Patents

Among his latest innovations, Ikeda has patented 1,4-dihydropyridine compounds, specifically those substituted with 5-membered heteroaryl groups, which demonstrate potential as bradykinin antagonists. These groundbreaking compounds are instrumental in advancing treatment options for a variety of medical conditions.

Career Highlights

Throughout his career, Takafumi Ikeda has been associated with prominent pharmaceutical companies, including Pfizer Corporation and Warner-Lambert Company. His work within these esteemed organizations has allowed him to hone his expertise in drug development and innovation, significantly contributing to the pharmaceutical landscape.

Collaborations

Ikeda's inventive journey has been marked by collaboration with notable co-workers, including Rodney W. Stevens and Mitsuhiro Kawamura. These partnerships have fostered a dynamic exchange of ideas, enhancing the creative process and leading to the successful development of numerous patents.

Conclusion

In conclusion, Takafumi Ikeda's contributions to the field of pharmaceuticals through his innovative inventions and collaborative efforts are commendable. His dedication to advancing medicinal chemistry continues to influence healthcare and improve patient outcomes, establishing him as a prominent inventor in the realm of bradykinin antagonists.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.